INBX

SEC source: 0002007919-24-000064 · wk-form4_1732309427.xml · nonDerivative · entry 2

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child B

Disclosed balance after: 51,093

F1 · balance_after: The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0002007919-24-000064 · wk-form4_1732309427.xml · nonDerivative · entry 1

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child A

Disclosed balance after: 51,093

F1 · balance_after: The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0002007919-24-000051 · wk-form4_1728333250.xml · nonDerivative · entry 1

Vuori Kristiina MD · CIK 0001612627 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,443

SEC source: 0002007919-24-000049 · wk-form4_1726521147.xml · nonDerivative · entry 2

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Lappe Family Trust

Disclosed balance after: 705,548

F3 · price: The shares were purchased in multiple transactions at prices ranging from $16.70 to $17.695, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

SEC source: 0002007919-24-000049 · wk-form4_1726521147.xml · nonDerivative · entry 1

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Lappe Family Trust

Disclosed balance after: 692,511

F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

SEC source: 0002007919-24-000047 · wk-form4_1726175657.xml · nonDerivative · entry 2

Vuori Kristiina MD · CIK 0001612627 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,776

F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.08, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000045 · wk-form4_1726002051.xml · nonDerivative · entry 3

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Lappe Family Trust

Disclosed balance after: 665,548

F4 · price: The shares were purchased in multiple transactions at prices ranging from $15.01 to $15.26, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

SEC source: 0002007919-24-000047 · wk-form4_1726175657.xml · nonDerivative · entry 1

Vuori Kristiina MD · CIK 0001612627 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,319

SEC source: 0002007919-24-000045 · wk-form4_1726002051.xml · nonDerivative · entry 2

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Lappe Family Trust

Disclosed balance after: 657,048

F3 · price: The shares were purchased in multiple transactions at prices ranging from $15.08 to $15.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

SEC source: 0002007919-24-000045 · wk-form4_1726002051.xml · nonDerivative · entry 1

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Lappe Family Trust

Disclosed balance after: 647,548

F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.04 to $15.70, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

SEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 4

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lappe Descendants' Trust

Disclosed balance after: 165,000

F5 · price: The shares were purchased in multiple transactions at prices ranging from $16.115 to $16.465, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

SEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 3

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lappe Descendants' Trust

Disclosed balance after: 160,288

F4 · price: The shares were purchased in multiple transactions at prices ranging from $15.115 to $16.11, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

SEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 2

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lappe Descendants' Trust

Disclosed balance after: 145,000

F3 · price: The shares were purchased in multiple transactions at prices ranging from $13.96 to $14.13, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

SEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 1

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lappe Descendants' Trust

Disclosed balance after: 135,000

F1 · price: The shares were purchased in multiple transactions at prices ranging from $13.9079 to $14.245, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

SEC source: 0001739614-24-000035 · wk-form4_1725395257.xml · nonDerivative · entry 1

Vuori Kristiina MD · CIK 0001612627 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,140

SEC source: 0002007919-24-000042 · wk-form4_1725048989.xml · nonDerivative · entry 1

MANHARD KIMBERLY · CIK 0001202094 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012

Disclosed balance after: 10,000

F1 · price: The shares were purchased in multiple transactions at prices ranging from $13.925 to $14.04, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012.

SEC source: 0002007919-24-000040 · wk-form4_1724704006.xml · nonDerivative · entry 2

FORSYTH DOUGLAS · CIK 0001240801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001

Disclosed balance after: 224,564

F3 · price: The shares were purchased in multiple transactions at prices ranging from $13.48 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001.

SEC source: 0002007919-24-000040 · wk-form4_1724704006.xml · nonDerivative · entry 1

FORSYTH DOUGLAS · CIK 0001240801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001

Disclosed balance after: 164,752

F1 · price: The shares were purchased in multiple transactions at prices ranging from $12.80 to $13.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001.

SEC source: 0002007919-24-000038 · wk-form4_1724358581.xml · nonDerivative · entry 2

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · The Mark Paul Lappe Roth IRA

Disclosed balance after: 54,865

F2 · price: The shares were purchased in multiple transactions at prices ranging from $12.82 to $13.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000038 · wk-form4_1724358581.xml · nonDerivative · entry 1

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · The Mark Paul Lappe Roth IRA

Disclosed balance after: 41,920

F1 · price: The shares were purchased in multiple transactions at prices ranging from $12.77 to $13.14, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000024 · wk-form4_1719264429.xml · nonDerivative · entry 3

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child B

Disclosed balance after: 16,250

F4 · kind: This transaction involved a gift of 10,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0002007919-24-000024 · wk-form4_1719264429.xml · nonDerivative · entry 2

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child A

Disclosed balance after: 16,250

F3 · kind: This transaction involved a gift of 10,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0002007919-24-000024 · wk-form4_1719264429.xml · nonDerivative · entry 1

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 1,061,360

F1 · kind: This transaction involved a gift of 89,050 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's children, relatives, and other individuals. Of the shares gifted, 40,000 shares were gifted to the reporting person's adult children not residing in the reporting person's household, 22,825 shares were gifted to trusts for the benefit of individuals not residing in the reporting person's household, 4,150 shares were gifted to relatives not residing in the reporting person's household, and 2,075 shares were gifted to a UTMA for the benefit of a minor not residing in the reporting person's household, in each case to which the reporting person does not have a beneficial interest.

F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0002007919-24-000008 · wk-form4_1717797906.xml · nonDerivative · entry 2

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 1,150,410

F2 · price: The shares were purchased in multiple transactions at prices ranging from $17.81 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000008 · wk-form4_1717797906.xml · nonDerivative · entry 1

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 1,142,145

F1 · price: The shares were purchased in multiple transactions at prices ranging from $16.81 to $17.805, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 5

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 1,092,861

F5 · price: The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 4

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 1,069,135

F4 · price: The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 3

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 1,003,798

F3 · price: The shares were purchased in multiple transactions at prices ranging from $17.40 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 2

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 923,060

F2 · price: The shares were purchased in multiple transactions at prices ranging from $16.25 to $16.75, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 1

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 876,268

F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.75 to $16.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0000950142-24-001491 · es240484861_4-forsyth.xml · derivative · entry 2

FORSYTH DOUGLAS · CIK 0001240801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-30

F3 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

F4 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date.

SEC source: 0000950142-24-001494 · es240484864_4-manhard.xml · derivative · entry 1

MANHARD KIMBERLY · CIK 0001202094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-30

F1 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

F2 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date.

SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · derivative · entry 4

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-30

F5 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

F6 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person?s continued service through such date.

SEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · derivative · entry 4

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-05-30

F4 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

F5 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

SEC source: 0000950142-24-001495 · es240484865_4-vuori.xml · derivative · entry 1

Vuori Kristiina MD · CIK 0001612627 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-30

F1 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

F2 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date.

SEC source: 0000950142-24-001490 · es240484860_4-eckelman.xml · derivative · entry 4

Eckelman Brendan P. · CIK 0001766433 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2034-05-30

F5 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

F6 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

SEC source: 0000950142-24-001489 · es240484859_4-deck.xml · derivative · entry 1

Deck Kelly · CIK 0001819427 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2034-05-30

F1 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

F2 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

SEC source: 0000950142-24-001491 · es240484861_4-forsyth.xml · nonDerivative · entry 1

FORSYTH DOUGLAS · CIK 0001240801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001

Disclosed balance after: 149,564

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F2 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001.

SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · nonDerivative · entry 3

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child B

Disclosed balance after: 6,250

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F4 · ownership.nature: These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · nonDerivative · entry 2

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child A

Disclosed balance after: 6,250

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F3 · ownership.nature: These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · nonDerivative · entry 1

Kayyem Jon Faiz · CIK 0001366268 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust

Disclosed balance after: 806,075

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

SEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · nonDerivative · entry 3

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · The Mark Paul Lappe Roth IRA

Disclosed balance after: 14,865

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

SEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · nonDerivative · entry 2

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: 125,000

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F3 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

SEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · nonDerivative · entry 1

Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Lappe Family Trust

Disclosed balance after: 621,548

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

SEC source: 0000950142-24-001490 · es240484860_4-eckelman.xml · nonDerivative · entry 3

Eckelman Brendan P. · CIK 0001766433 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: 40,000

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F4 · ownership.nature: These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.

SEC source: 0000950142-24-001490 · es240484860_4-eckelman.xml · nonDerivative · entry 2

Eckelman Brendan P. · CIK 0001766433 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: 40,000

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F3 · ownership.nature: These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.

SEC source: 0000950142-24-001490 · es240484860_4-eckelman.xml · nonDerivative · entry 1

Eckelman Brendan P. · CIK 0001766433 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Eckelman Living Trust Dated February 5, 2014

Disclosed balance after: 433,888

F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

F2 · ownership.nature: These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014.

SEC source: 0000950170-24-067359 · ownership.xml · nonDerivative · entry 1

Inhibrx, Inc. · CIK 0001739614 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,157,926

F1 · security: On January 8, 2024, Inhibrx, Inc. ("RemainCo"), acquired 100 shares, par value $0.0001 per share (the "Common Stock"), of Inhibrx Biosciences, Inc. (the "Issuer"), which at the time constituted all of the issued and outstanding Common Stock of the Issuer. On May 29, 2024, the Common Stock was split, resulting in RemainCo's ownership of an aggregate 14,474,066 shares of Common Stock of the Issuer.

F2 · kind: On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024.

F2 · price: On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024.